Earnings Call Summary | OptimizeRx(OPRX.US) Q2 2024 Earnings Conference
Earnings Call Summary | OptimizeRx(OPRX.US) Q2 2024 Earnings Conference
A net loss was reported at $4 million, an improvement from a $4.1 million loss in the same period last year.The following is a summary of the OptimizeRx Corporation (OPRX) Q2 2024 Earnings Call Transcript:
以下是Optimizerx公司(OPRX) 2024年第二季度業績會議通話摘要：
Financial Performance:
金融業績：
OptimizeRx reported a 36% year-over-year revenue growth in Q2, marking a rise from $13.8 million in the previous year to $18.8 million.
Gross margin increased to 62.2% compared to 56.6% year-over-year, attributed to higher DAAP-related revenue and a favorable channel partner mix.
A net loss was reported at $4 million, an improvement from a $4.1 million loss in the same period last year.
Adjusted EBITDA was positive at $0.5 million, reversing from a $0.8 million loss in Q2 2023.
OptimizeRx在Q2中報告了36%的年同比營業收入增長，從上一年的1380萬美元上升至1880萬美元。
毛利率同比上升到62.2％，歸因於更高的DAAP相關營收和有利的渠道合作伙伴組合。
淨虧損爲400萬美元，較去年同期的410萬美元虧損有所改善。
調整後的EBITDA爲正50萬美元，在Q2 2023年的80萬美元虧損基礎上逆轉。
Business Progress:
業務進展：
OptimizeRx closed 17 DAAP deals in the first half of 2024, including eight in Q2, demonstrating the strength and appeal of their DAAP and proprietary network platforms.
The company continues to convert its pipeline into closed DAAP deals, aiming to transition over 300 brands currently supported to DAAP.
OptimizeRx在2024年上半年完成了17項DAAP交易，其中包括Q2的8項，展示了其DAAP和專有網絡平台的實力和吸引力。
該公司正在將其流水線轉化爲已關閉的DAAP交易，旨在將目前支持的300個品牌轉換爲DAAP。
Opportunities:
機會：
Significant momentum in patronage from pharma companies, highlighting an opportunity for future revenue growth through the enhanced DAAP platform.
The potential to increase average revenue per client, particularly for the top 20 pharma clients, based on their growing commitment and increased budget allocation towards OptimizeRx's solutions.
藥品公司的重要支持與促進，突顯了通過增強的DAAP平台實現未來營收增長的機會。
可以增加每個客戶的平均營收，特別是針對前20個藥品客戶，基於他們日益增長的承諾和對OptimizeRx解決方案預算分配的增加。
Risks:
風險：
Timely internal approvals required for DAAP deals could delay revenue recognition, as seen with a $6 million multi-brand DAAP program which was postponed to Q3 due to delayed client approvals.
DAAP交易所需的及時內部批准可能會延遲收入確認，如一項600萬美元的多品牌DAAP計劃，由於客戶批准延遲而推遲到Q3。
More details: OptimizeRx IR
更多詳情：Optimizerx IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
